// App-Quantinova.ai

FRI0297 : COMPARISON OF EFFICACY OF SECUKINUMAB VS ANTI-TNF AS SECOND LINE BIOLOGIC THERAPY IN AXIAL SPONDYLOARTHROPATHY BASED ON BASDAI RESPONSE IN AN OBSERVATIONAL STUDY

Researchers

Presenter

  • O. Weston

Principal Investigators

  • R. Thomas

  • R. Adshead

  • S. Donnelly

  • A. Pakozdi

  • N. Purkayastha

Medical Centers

  • Barts and the London School of Medicine, London, United Kingdom

  • Whipps Cross University Hospital, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

  • Spondyloarthritis

  • Axial spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved